Advances in Therapy

, Volume 18, Issue 2, pp 67–74

Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia

  • Hui-Chi Hsu
  • Jyh-Pyng Gau
  • Jacqueline Ming Liu
  • Wing-Keung Chau
  • Chao-Hung Ho
Article

Abstract

Intensive postremission chemotherapy has produced disease-free survival comparable to that of bone marrow transplantation in patients with acute myelogenous leukemia (AML), but its efficacy was unknown in Taiwan. We assessed the efficacy of intensive postremission chemotherapy, consisting of high-dose arabinoside-C (HiDAC) with or without transplantation of peripheral blood stem cells, in 33 AML patients from a single institute in Taiwan. Toxic reactions, treatment outcome, prognostic factors, and the size of the peripheral blood stem-cell harvest after HiDAC were analyzed. After a median follow-up of 21 months, 18 patients remained in continuous complete remission. The actuarial leukemia-free survival at 4 years was 51%. Relapse occurred in 12 patients, at a median of 12 months after initial diagnosis. All 6 patients with acute promyelocytic leukemia remained disease free after HiDAC therapy. Age, sex, and number of remission-induction or intensive consolidation chemotherapy courses had no effect on the risk of relapse. Intensive postremission chemotherapy can effectively prolong the duration of remission in young (<60 years of age) adults with AML.

Keywords

acute myelogenous leukemia postremission therapy high-dose arabinoside peripheral blood stem-cell transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin R, Gale R. Acute myelogenous leukemia: recent advances in therapy.Blood 1987;69: 1551–1562.PubMedGoogle Scholar
  2. 2.
    Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelogenous leukemia: a study by Cancer and Leukemia Group B.Blood 1981;58:1203–1212.PubMedGoogle Scholar
  3. 3.
    Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: a review.Leukemia. 1988;2:253–260.PubMedGoogle Scholar
  4. 4.
    Mayer RM, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myelogenous leukemia.N Engl J Med. 1994;331:896–903.PubMedCrossRefGoogle Scholar
  5. 5.
    Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission.Blood. 1992; 79:3380–3387.PubMedGoogle Scholar
  6. 6.
    Bortin MM, Horowitz MM, Rowlings PA, et al. 1993 Progress report from the International Bone Marrow Transplant Registry.Bone Marrow Transplant. 1993;12:97–104.PubMedGoogle Scholar
  7. 7.
    Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.Blood. 1991;77:1429–1435.PubMedGoogle Scholar
  8. 8.
    Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia.N Engl J Med. 1995;332:217–223.PubMedCrossRefGoogle Scholar
  9. 9.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of acute leukemias.Br J Haematol. 1976;33:451–458.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.J Clin Oncol. 1990;8:813–819.PubMedGoogle Scholar
  11. 11.
    Hsu HC, Tsai WH, Lin JS, Tzeng CH, Wang SY, Ho CH. Primary transplantation of allogeneic peripheral blood stem cells for severe aplastic anemia.Ann Hematol. 1997;74:191–192.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc. 1958;53:457.CrossRefGoogle Scholar
  13. 13.
    Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.Blood. 1992;80: 2977–2978.PubMedGoogle Scholar
  14. 14.
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.N Engl J Med. 1998;339:1649–1656.PubMedCrossRefGoogle Scholar
  15. 15.
    Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy.Bone Marrow Transplant. 1991;7(suppl 3):9–12.PubMedGoogle Scholar
  16. 16.
    Lowenberg B. Postremission treatment of acute myelogenous leukemia (editorial).N Engl J Med. 1995;332:260–262.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission. Long-term follow-up and results.J Clin Oncol. 1989;7:1260–1267.PubMedGoogle Scholar
  18. 18.
    Mandelli F, Vegna ML, Avvisati G, et al. A randomized study of the efficacy of post-consolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.Ann Hematol. 1992;64:166–172.PubMedCrossRefGoogle Scholar
  19. 19.
    Elonen E, Almqvist A, Hanninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.Leukemia. 1998;12;1041–1048.PubMedCrossRefGoogle Scholar
  20. 20.
    Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM).Blood. 1997;90:2978–2986.PubMedGoogle Scholar
  21. 21.
    Stein AS, O’Donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.J Clin Oncol. 1996;14:2206–2216.PubMedGoogle Scholar
  22. 22.
    Fenaux P, Chastang C, Chevert S, et al. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.Blood. 1999;94:1192–1200.PubMedGoogle Scholar
  23. 23.
    Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia.N Engl J Med. 1997;337:1021–1028.PubMedCrossRefGoogle Scholar
  24. 24.
    Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.J Clin Oncol. 1997;15:483–490.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2001

Authors and Affiliations

  • Hui-Chi Hsu
    • 1
  • Jyh-Pyng Gau
    • 1
  • Jacqueline Ming Liu
    • 1
  • Wing-Keung Chau
    • 1
  • Chao-Hung Ho
    • 1
  1. 1.Division of Hematology Department of Medicine Taipei-Veterans General Hospital School of MedicineNational Yang-Ming University National Health Research InstitutesTaipeiTaiwan

Personalised recommendations